Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290804080> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4290804080 endingPage "602" @default.
- W4290804080 startingPage "593" @default.
- W4290804080 abstract "In this study we examined the relationship between urate levels at baseline and functional change measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score after edaravone treatment.Data from the edaravone trials MCI186-16, MCI186-17, and MCI186-19 were analyzed, including the following treatment sequence groups: edaravone-edaravone (EE, n = 113); edaravone-placebo (EP, n = 45); and placebo-edaravone (PE, n = 146). Subgroups were defined as low baseline urate (below the median value of 4.8 mg/dL) and high baseline urate (≥4.8 mg/dL). The differences in ALSFRS-R total score change and urate change were evaluated using the mixed model for repeated measurement for overall population, by urate-level subgroup, and by trial.Compared with the PE group, the EE group showed a slower decline in ALSFRS-R score, regardless of the urate baseline level, and a slower decline in urate level in the higher baseline urate subgroup. Smaller changes in ALSFRS-R score and urate were observed in patients diagnosed with probable, laboratory-supported ALS. There was a positive correlation between changes from baseline to cycle 12 in urate levels and ALSFRS-R score.Edaravone treatment in ALS patients diagnosed with definite ALS or probable ALS showed slowing of disease progression, regardless of baseline urate level. In addition, because edaravone treatment was associated with a slower decline in urate level in the higher baseline urate subgroup and urate-level changes were associated with changes in ALSFRS-R score, urate level, and/or change may be one indicator in predicting disease progression after edaravone administration." @default.
- W4290804080 created "2022-08-12" @default.
- W4290804080 creator A5020086982 @default.
- W4290804080 creator A5020403627 @default.
- W4290804080 creator A5022850761 @default.
- W4290804080 creator A5050956962 @default.
- W4290804080 creator A5068098432 @default.
- W4290804080 creator A5088477439 @default.
- W4290804080 date "2022-09-02" @default.
- W4290804080 modified "2023-10-16" @default.
- W4290804080 title "Associations between the <scp>ALSFRS‐R</scp> score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of <scp>ALSFRS‐R</scp> scores in clinical studies <scp>MCI186</scp> ‐16, <scp>MCI186</scp> ‐17, and <scp>MCI186</scp> ‐19" @default.
- W4290804080 cites W1936774212 @default.
- W4290804080 cites W2000411175 @default.
- W4290804080 cites W2005243883 @default.
- W4290804080 cites W2025372788 @default.
- W4290804080 cites W2034454495 @default.
- W4290804080 cites W2038540507 @default.
- W4290804080 cites W2052542747 @default.
- W4290804080 cites W2077612318 @default.
- W4290804080 cites W2127922258 @default.
- W4290804080 cites W2128167427 @default.
- W4290804080 cites W2135000377 @default.
- W4290804080 cites W2523856518 @default.
- W4290804080 cites W2616124858 @default.
- W4290804080 cites W2791065855 @default.
- W4290804080 cites W2950589943 @default.
- W4290804080 cites W4220767271 @default.
- W4290804080 cites W4249220977 @default.
- W4290804080 doi "https://doi.org/10.1002/mus.27700" @default.
- W4290804080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36053970" @default.
- W4290804080 hasPublicationYear "2022" @default.
- W4290804080 type Work @default.
- W4290804080 citedByCount "0" @default.
- W4290804080 crossrefType "journal-article" @default.
- W4290804080 hasAuthorship W4290804080A5020086982 @default.
- W4290804080 hasAuthorship W4290804080A5020403627 @default.
- W4290804080 hasAuthorship W4290804080A5022850761 @default.
- W4290804080 hasAuthorship W4290804080A5050956962 @default.
- W4290804080 hasAuthorship W4290804080A5068098432 @default.
- W4290804080 hasAuthorship W4290804080A5088477439 @default.
- W4290804080 hasConcept C126322002 @default.
- W4290804080 hasConcept C142724271 @default.
- W4290804080 hasConcept C1862650 @default.
- W4290804080 hasConcept C204787440 @default.
- W4290804080 hasConcept C27081682 @default.
- W4290804080 hasConcept C2779134260 @default.
- W4290804080 hasConcept C2779554857 @default.
- W4290804080 hasConcept C2779881121 @default.
- W4290804080 hasConcept C2780596555 @default.
- W4290804080 hasConcept C2908647359 @default.
- W4290804080 hasConcept C67761136 @default.
- W4290804080 hasConcept C71924100 @default.
- W4290804080 hasConcept C99454951 @default.
- W4290804080 hasConceptScore W4290804080C126322002 @default.
- W4290804080 hasConceptScore W4290804080C142724271 @default.
- W4290804080 hasConceptScore W4290804080C1862650 @default.
- W4290804080 hasConceptScore W4290804080C204787440 @default.
- W4290804080 hasConceptScore W4290804080C27081682 @default.
- W4290804080 hasConceptScore W4290804080C2779134260 @default.
- W4290804080 hasConceptScore W4290804080C2779554857 @default.
- W4290804080 hasConceptScore W4290804080C2779881121 @default.
- W4290804080 hasConceptScore W4290804080C2780596555 @default.
- W4290804080 hasConceptScore W4290804080C2908647359 @default.
- W4290804080 hasConceptScore W4290804080C67761136 @default.
- W4290804080 hasConceptScore W4290804080C71924100 @default.
- W4290804080 hasConceptScore W4290804080C99454951 @default.
- W4290804080 hasFunder F4320327566 @default.
- W4290804080 hasIssue "5" @default.
- W4290804080 hasLocation W42908040801 @default.
- W4290804080 hasLocation W42908040802 @default.
- W4290804080 hasOpenAccess W4290804080 @default.
- W4290804080 hasPrimaryLocation W42908040801 @default.
- W4290804080 hasRelatedWork W2128167427 @default.
- W4290804080 hasRelatedWork W2787343175 @default.
- W4290804080 hasRelatedWork W2917925658 @default.
- W4290804080 hasRelatedWork W2970031887 @default.
- W4290804080 hasRelatedWork W2981269454 @default.
- W4290804080 hasRelatedWork W3028527693 @default.
- W4290804080 hasRelatedWork W3095162650 @default.
- W4290804080 hasRelatedWork W4248518818 @default.
- W4290804080 hasRelatedWork W4249220977 @default.
- W4290804080 hasRelatedWork W4291007035 @default.
- W4290804080 hasVolume "66" @default.
- W4290804080 isParatext "false" @default.
- W4290804080 isRetracted "false" @default.
- W4290804080 workType "article" @default.